NEWARK, Del.--(BUSINESS WIRE)--Uvax Bio, LLC, a privately held, preclinical-stage vaccine development company, today announced that Dr. Jiang Zhu, Associate Professor of Integrative Structural and Computational Biology at Scripps Research, and Co-founder of Uvax Bio, LLC will be presenting a review of the development of Uvax Bio’s HIV-1 vaccine candidates including the latest results from the company’s preclinical studies confirming safety and immunogenicity in rodent models.

NEWARK，Del。--（BUSINESS WIRE）-Uvax Bio，LLC，一家私营的临床前阶段疫苗开发公司，今天宣布，斯克里普斯研究所综合结构和计算生物学副教授朱江博士，共同创始人Uvax Bio，LLC将对Uvax Bio的HIV-1候选疫苗的开发进行审查，包括公司临床前研究的最新结果，证实啮齿动物模型的安全性和免疫原性。

The presentation will be during the World Vaccine Congress – West Coast in Santa Clara, California on November 30th..

演讲将于11月30日在加利福尼亚州圣克拉拉举行的世界疫苗大会-西海岸举行。。

Dr. Zhu invented the UFO HIV antigen trimer and utilized his single-component self-assembling protein nanoparticle (1c-SApNP®) vaccine platform technology to produce the two vaccines that were used in the preclinical program. Zhu added the innovative step to further modify his vaccine with a process called glycan trimming which demonstrated enhanced immune responses in the studies.

朱博士发明了UFO HIV抗原三聚体，并利用其单组分自组装蛋白纳米粒子（1CSAPNP®）疫苗平台技术生产用于临床前计划的两种疫苗。朱增加了创新步骤，进一步修改他的疫苗，称为聚糖修剪过程，在研究中证明了增强的免疫反应。

The glycan trimming approach – referred to as “low-sugar vaccination” - was recently named one of IUPAC’s Top Ten Emerging Technologies in Chemistry. The 1c-SApNP platform technology and HIV-1 vaccine candidates have been exclusively licensed to Uvax Bio under a comprehensive agreement with Scripps Research..

聚糖修剪方法-被称为“低糖疫苗接种”-最近被命名为IUPAC十大新兴化学技术之一。根据与Scripps Research的全面协议，1c SApNP平台技术和HIV-1候选疫苗已获得Uvax Bio的独家许可。。

Animal Studies Show High Response Rates and Broad Neutralization

动物研究显示高反应率和广泛中和

In a recent preclinical immunogenicity study in rats, Uvax Bio tested its HIV-1 vaccines (UVAX-1107 and UVAX-1197) in different regimens, each combined with CpG 1018® adjuvant (Dynavax Technologies Corporation) and Alhydrogel® (Croda). Overall, immunization with Uvax’s HIV-1 vaccines elicited robust autologous tier 2 neutralization, with >93% showing positive neutralization.

在最近的大鼠临床前免疫原性研究中，Uvax-Bio以不同的方案测试其HIV-1疫苗（Uvax-1107和Uvax-1197），每种方案均与CpG1018®佐剂（Dynavax Technologies Corporation）和Alhydrogel®（Croda）组合。总体而言，用Uvax的HIV-1疫苗免疫引发强烈的自体tier 2中和，>93%显示阳性中和。

Furthermore, preliminary neutralization screening against a 12-virus panel of heterologous tier 2 HIV-1 pseudoviruses shows that 54 out of 72 rats tested thus far (75%) showed ≥ 50% neutralization against at least one non-vaccine-matched pseudovirus..

此外，针对异源2级HIV-1假病毒的12病毒组的初步中和筛选显示，迄今为止测试的72只大鼠中有54只（75%）对至少一种非疫苗匹配的假病毒显示≥50%的中和。。

“Our preclinical studies have confirmed both the safety and robust immunogenicity of our vaccine candidates for HIV-1. These data combined with our completed GMP manufacturing of the vaccine supplies were the final steps in our preparation for human trials,” said Ji Li, Ph.D., Chief Executive Officer of Uvax Bio..

“我们的临床前研究证实了我们的HIV-1候选疫苗的安全性和强大的免疫原性。这些数据与我们完成的疫苗供应GMP生产相结合，是我们准备人体试验的最后一步，“Uvax Bio首席执行官Ji Li博士说。。

About Uvax Bio

关于Uvax Bio

Uvax Bio, a spin-off vaccine company from Scripps Research, employs proprietary 1c-SApNP® platform technology invented by Dr. Jiang Zhu of Scripps Research to develop and commercialize prophylactic vaccines to prevent life-threatening infectious diseases. The vaccines in development by Uvax Bio present a virus-sized protein nanoparticle with many copies of the antigen in its pre-fusion state.

来自Scripps Research的衍生疫苗公司Uvax Bio采用Scripps Research的Jiang Zhu博士发明的专有1CSAPNP®平台技术开发和商业化预防性疫苗，以预防危及生命的传染病。由Uvax-Bio开发的疫苗呈递病毒大小的蛋白质纳米颗粒，其具有处于其融合前状态的许多抗原拷贝。

Animal studies have confirmed robust levels of broadly neutralizing antibodies in multiple disease states. Uvax Bio holds the exclusive worldwide rights to the 1c-SApNP® platform and an expanding portfolio of 12 patented preclinical optimized vaccine candidates. In addition to the leading candidates in HIV-1, Uvax is also working to advance universal influenza and RSV/hMPV vaccines.

动物研究已经证实在多种疾病状态下广泛中和抗体的稳健水平。Uvax Bio拥有1CSAPNP®平台的独家全球权利，以及不断扩大的12种专利临床前优化候选疫苗组合。除了HIV-1的主要候选者之外，Uvax还致力于推进通用流感和RSV/hMPV疫苗。

The 1c-SApNP technology enables the production of virus-like protein particles that can display 20-60 pre-fusion stabilized antigens targeting a wide range of viral and bacterial diseases. The vaccines are produced using a single step, universal, cell-based manufacturing process..

1c SApNP技术能够生产病毒样蛋白质颗粒，可以显示针对多种病毒和细菌疾病的20-60种融合前稳定抗原。疫苗采用单步，通用，基于细胞的制造工艺生产。。

For more information on Uvax Bio, visit www.uvaxbio.com.

有关Uvax Bio的更多信息，请访问www.uvaxbio.com。